RPA-601 by Rocket Pharmaceuticals for Cardiomyopathy: Likelihood of Approval

RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.

Pfizer gene therapy reduced hemophilia bleeds, but questions remain

Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for at least 15 months in a large phase 3 trial.

July 24, 2024

RP-12146 by Rhizen Pharmaceuticals for Gastric Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

June 19, 2024

Study sheds light on global laboratory-acquired infections and pathogen escapes

Study analyzes global incidents of laboratory-acquired infections and accidental pathogen escapes from 2000 to 2021, highlighting the need for improved biosafety protocols and reporting systems.

December 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.